Semin intervent Radiol 2015; 32(02): 225-230
DOI: 10.1055/s-0035-1549845
Morbidity and Mortality
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hepatoma Rupture following Drug-Eluting Bead Chemoembolization

Noah Schwind
1   Department of Radiology, Northwestern Memorial Hospital, Chicago, Illinois
,
Charles E. Ray Jr.
2   Department of Radiology, University of Illinois at Chicago, Chicago, Illinois
,
Ron C. Gaba
2   Department of Radiology, University of Illinois at Chicago, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
28 May 2015 (online)

Rupture of hepatocellular carcinoma (HCC) represents a devastating and potentially fatal complication of both the underlying disease and the tumor posttransarterial treatment. Early recognition of the complication and aggressive management is usually mandatory to effectively treat the hemorrhagic sequelae arising from the rupture. A low threshold for suspicion of rupture is mandatory in any patient presenting with significant abdominal pain, particularly if sudden in onset, and/or hemodynamic instability. The following article describes two cases of HCC rupture postchemoembolization (transarterial chemoembolization [TACE]) as well as a brief literature review of this disease process.

 
  • References

  • 1 Xia J, Ren Z, Ye S , et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol 2006; 59 (3) 407-412
  • 2 Ferlay J, Soerjomataram I, Ervik M , et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. . Available at: http://globocan.iarc.fr . Accessed July 17, 2014
  • 3 Battula N, Srinivasan P, Madanur M , et al. Ruptured hepatocellular carcinoma following chemoembolization: a western experience. Hepatobiliary Pancreat Dis Int 2007; 6 (1) 49-51
  • 4 Vogl TJ, Naguib NN, Nour-Eldin NE , et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 2009; 72 (3) 505-516
  • 5 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37 (2) 429-442
  • 6 Reso A, Ball CG, Sutherland FR, Bathe O, Dixon E. Rupture and intra-peritoneal bleeding of a hepatocellular carcinoma after a transarterial chemoembolization procedure: a case report. Cases J 2009; 2 (1) 68
  • 7 Takayasu K, Arii S, Ikai I , et al; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131 (2) 461-469
  • 8 Jia Z, Tian F, Jiang G. Ruptured hepatic carcinoma after transcatheter arterial chemoembolization. Curr Ther Res Clin Exp 2013; 74: 41-43
  • 9 Sun Z, Li G, Ai X , et al. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. Crit Rev Oncol Hematol 2011; 79 (2) 164-174
  • 10 Nawawi O, Hazman M, Abdullah B , et al. Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience. Biomed Imaging Interv J 2010; 6 (1) e7
  • 11 Liu CL, Ngan H, Lo CM, Fan ST. Ruptured hepatocellular carcinoma as a complication of transarterial oily chemoembolization. Br J Surg 1998; 85 (4) 512-514
  • 12 Aoki T, Kokudo N, Matsuyama Y , et al; Liver Cancer Study Group of Japan. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg 2014; 259 (3) 532-542
  • 13 Rossetto A, Adani GL, Risaliti A , et al. Combined approach for spontaneous rupture of hepatocellular carcinoma. World J Hepatol 2010; 2 (1) 49-51